Yarrow Bioscience, Inc. Common Stock
YARW
19 hedge funds and large institutions have $1.54M invested in Yarrow Bioscience, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 0 closing their positions.
12% more funds holding
Funds holding: 17 → 19 (+2)
0.01% less ownership
Funds ownership: 0.24% → 0.23% (-0.01%)
5% less capital invested
Capital invested by funds: $1.63M → $1.54M (-$87.9K)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
US Bancorp
Minneapolis,
Minnesota
|
+$19.4K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$11.3K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$3.49K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.09K |
| 5 |
JP Morgan Chase
New York
|
+$655 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$44.1K |
| 2 |
BlackRock
New York
|
-$18.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$3.93K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$3.49K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.84K |
YARW Hedge Fund Activity: Q3 2023 in Review
19 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience, Inc. Common Stock (YARW) for Q3 2023, worth a combined $1.54M — down 5.4% from $1.63M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new YARW positions and 0 closed out — a net gain of 3 holders — while 2 added to existing stakes and 5 trimmed.
The largest buyer was US Bancorp, opening a new position worth an estimated $19.4K. The largest seller was Renaissance Technologies, cutting an estimated $44.1K.
- 19 institutional investors held Yarrow Bioscience, Inc. Common Stock (YARW) as of Q3 2023, up from 17 in Q2 2023.
- Funds reported $1.54M of Yarrow Bioscience, Inc. Common Stock stock for Q3 2023, down 5.4% quarter-over-quarter.
- 3 funds opened new Yarrow Bioscience, Inc. Common Stock positions in Q3 2023 and 0 closed out, a net change of +3 holders.
- The largest Yarrow Bioscience, Inc. Common Stock buyer in Q3 2023 was US Bancorp, an estimated $19.4K added.
- The largest Yarrow Bioscience, Inc. Common Stock seller in Q3 2023 was Renaissance Technologies, an estimated $44.1K sold.
Based on aggregated 13F filings for Q3 2023.